Carcinogenesis and transcriptional regulation through Maf recognition elements

Cancer Science

Volumn 98, Issue 2, 2007, Pages 135-139

  Motohashi, Hozumi ^a   Yakamoto, Masayuki ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KEAP1 PROTEIN; LEUCINE ZIPPER PROTEIN; METALLOPROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR MAF; TRANSCRIPTION FACTOR NRF2; XENOBIOTIC AGENT;

CANCER CELL; CANCER CELL CULTURE; CANCER GENETICS; CARCINOGENESIS; CELL PROLIFERATION; CELL PROTECTION; CYTOLOGY; DIMERIZATION; GENE ACTIVATION; GENE ACTIVITY; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC REGULATION; GENETIC STABILITY; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MICROENVIRONMENT; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; REVIEW; STEM CELL; STRESS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAF TRANSCRIPTION FACTORS; OXIDATIVE STRESS; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC;

EID: 33845682863     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00358.x     Document Type: Review

References (51)

1. Huff J. Long-term chemical carcinogenesis bioassays predict human cancer hazards: Issues, controversies, and uncertainties. Ann NY Acad Sci 1999; 895: 56-79.
2. Heather L, Van E. Peyton Rous: Father of the tumor virus. J Exp Med 2005; 201: 320.
3. Vogelstein B, Kinzler KW. Cancer genes and the pathway they control. Nat Med 2004; 10: 789-99.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
5. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJA. The origin of the cancer stem cell: Current controversies and new insights. Nat Rev Cancer 2005; 5: 899-904.
6. Nishizawa M, Kataoka K, Goto N, Fujiwara KT, Kawai S. v-maf, a viral oncogene that encodes a leucine zipper motif. Proc Natl Acad Sci USA 1989; 86: 7711-5.
7. Motohashi H, O'Connor T, Katsuoka F, Engel JD, Yamamoto M. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene 2001; 294: 1-12.
8. Kataoka K, Noda M, Nishizawa M. Maf nuclear oncoprotein recognizes sequences related to an AP-1 site and forms heterodimer with both Fos and Jun. Mol Cell Biol 1994; 14: 700-12.
9. Kerppola TK, Curran T. A conserved region adjacent to the basic domain is required for recognition of an extended DNA binding site by Maf/Nrl family proteins. Oncogene 1994; 9: 3149-58.
10. Lavin MF, Birrell G, Chen P, Kozlov S, Scott S, Gueven N. ATM signaling and genomic stability in response to DNA damage. Mutat Res 2005; 569: 123-32.
11. Nakabeppu Y, Sakumi K, Sakamoto K, Tsuchimoto D, Tsuzuki T, Nakatsu Y. Mutagenesis and carcinogenesis caused by the oxidation of nucleic acids. Biol Chem 2006; 387: 373-9.
12. Arai T, Kelly VP, Minowa O, Noda T, Nishimura S. The study using wild-type and Ogg1 knockout mice exposed to potassium bromate shows no tumor induction despite an extensive accumulation of 8-hydroxyguanine in kidney DNA. Toxicology 2006; 221: 179-86.
13. de Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev 1999; 13: 768-85.
14. Normanno N, de Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
15. Yamagata T, Maki K, Mitani K. Runx1/AML1 in normal and abnormal hematopoiesis. Int J Hematol 2005; 82: 1-8.
16. Lian Z, Di Cristofano A. Class reunion: PTEN joins the nuclear crew. Oncogene 2005; 24: 7394-400.
17. Taketo MM. Mouse models of gastrointestinal tumors. Cancer Sci 2006; 97: 355-61.
18. Maxwell PH. The HIF pathway in cancer. Semin Cell Dev Biol 2005; 16: 523-30.
19. Itoh K, Chiba T, Takahashi S et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-22.
20. Ishii T, Itoh K, Takahashi S et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000; 275: 16023-9.
21. Rushmore TH, Morton MR, Pickett CB. Transcriptional regulation of the rat NAD (P) H. quinone reductase gene. J Biol Chem 1991; 266: 11632-9.
22. Friling RS, Bensimon A, Tichauer Y, Daniel V. Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element. Proc Natl Acad Sci USA 1990; 87: 6258-62.
23. Motohashi H, Katsuoka F, Engel JD, Yamamoto M. Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. Proc Natl Acad Sci USA 2004; 101: 6379-84.
24. Katsuoka F, Motohashi H, Ishii T, Aburatani H, Engel JD, Yamamoto M. Genetic evidence that small maf proteins are essential for the activation of antioxidant response element-dependent genes. Mol Cell Biol 2005; 25: 8044-51.
25. Itoh K, Wakabayashi N, Katoh Y et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999; 13: 76-86.
26. Kobayashi A, Kang MI, Okawa H et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24: 7130-9.
27. Wakabayashi N, Itoh K, Wakabayashi J et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 2003; 35: 238-45.
28. Kobayashi M, Yamamoto M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Advan Enzyme Regul in press.
29. Tong KI, Kobayashi A, Yamamoto M. Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and a latch? Biol Chem in press.
30. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004; 10: 549-57.
31. Dinkova-Kostova AT, Holtzclaw WD, Wakabayashi N. Keap1, the sensor for electrophiles and oxidants that regulates the phase 2 response, is a zinc metalloprotein. Biochemistry 2005; 44: 6889-99.
32. Ramos-Gomez M, Kwak MK, Dolan PM et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 2001; 98: 3410-5.
33. Iida K, Itoh K, Kumagai Y et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 2004; 64: 6424-31.
34. auf dem Keller U, Huber M, Beyer TA et al. Nrf transcription factors in keratinocytes are essential for skin tumor prevention but not for wound healing. Mol Cell Biol 2006; 26: 3773-84.
35. Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K, Yamamoto M. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol Appl Pharmacol 2001; 173: 154-60.
36. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001; 357: 539-45.
37. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: A common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006; 56: 69-83.
38. Itoh K, Mochizuki M, Ishii Y et al. Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta (12,14)-prostaglandin j (2). Mol Cell Biol 2004: 24: 36-45.
39. Ishii Y, Itoh K, Morishima Y et al. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J Immunol 2005; 175: 6968-75.
40. Devling TW, Lindsay CD, McLellan LI, McMahon M, Hayes JD. Utility of siRNA against Keap1 as a strategy to stimulate a cancer chemopreventive phenotype. Proc Natl Acad Sci USA 2005; 102: 7280-5.
41. Okawa H, Motohashi H, Kobayashi A, Aburatani H, Kensler TW, Yamamoto M. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem Biophys Res Commun 2006; 339: 79-88.
42. Padmanabhan B, Tong KI, Ohta T et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 2006; 21: 689-700.
43. Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 2005; 33: 956-62.
44. Yamamoto T, Kyo M, Kamiya T et al. Predictive base substitution rules that determine the binding and transcriptional specificity of Maf recognition elements. Genes Cells 2006; 11: 575-91.
45. Hurt EM, Wiestner A, Rosenwald A et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191-9.
46. Morito N, Yoh K, Fujioka Y et al. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res 2006; 66: 812-9.
47. Kwak MK, Wakabayashi N, Kensler TW. Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat Res 2004; 555: 133-48.
48. Fahey JW, Haristoy X, Dolan PM et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci USA 2002; 99: 7610-5.
49. Morimitsu Y, Nakagawa Y, Hayashi K et al. A sulforaphane analogue that potently activates the Nrf2-dependent detoxification pathway. J Biol Chem 2002; 277: 3456-63.
50. Balogun E, Hoque M, Gong P et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 2003; 371: 887-95.
51. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: Characterization of the two-site molecular recognition model. Mol Cell Biol 2006; 26: 2887-900.